MARKET

SRNEQ

SRNEQ

Sorrento Therapeutics Inc
EXMKT
0.026
-0.004
-13.33%
Closed 15:59 02/28 EST
OPEN
0.027
PREV CLOSE
0.030
HIGH
0.036
LOW
0.026
VOLUME
55.97K
TURNOVER
1.49K
52 WEEK HIGH
3.090
52 WEEK LOW
0.010
MARKET CAP
12.27M
P/E (TTM)
-0.0239
1D
5D
1M
3M
1Y
5Y
Scilex and Sorrento settle with Virpax and its founder Anthony Mack
Scilex and Sorrento settle with Virpax and its founder Anthony Mack. The two companies have reached an agreement to settle a dispute with their rival. The settlement comes months after a Delaware court ruled in favor of Scilex in a lawsuit against the rival. VirpX Pharmaceuticals announced a reverse stock split on Tuesday.
Seeking Alpha · 2d ago
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics And Scilex Pharmaceuticals
As part of the settlement, Virpax will pay the plaintiffs royalties of 6% of annual net sales of products developed from drug candidates. The parties have agreed to a cash payment of $3.5 million to settle all claims against Vir pax. The settlement is expected to be completed in 2024.
Benzinga · 2d ago
Weekly Report: what happened at SRNEQ last week (0219-0223)?
Weekly Report · 3d ago
Sorrento faked venue in bankruptcy filing, Justice Department says
Healthcare Sorrento faked venue in bankruptcy filing, Justice Department says. The company and its subsidiary filed for Chapter 11 bankruptcy in February 2023. The Justice Department is urging the case to be dismissed or moved to another venue. Sorrenta Therapeutics and its publicly listed subsidiary Scilex stock fell sharply after the announcement.
Seeking Alpha · 02/21 17:34
Weekly Report: what happened at SRNEQ last week (0212-0216)?
Weekly Report · 02/19 11:27
Weekly Report: what happened at SRNEQ last week (0205-0209)?
Weekly Report · 02/12 11:17
Weekly Report: what happened at SRNEQ last week (0129-0202)?
Weekly Report · 02/05 11:25
Weekly Report: what happened at SRNEQ last week (0122-0126)?
Weekly Report · 01/29 11:14
More
About SRNEQ
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.

Webull offers Sorrento Therapeutics Inc stock information, including EXMKT: SRNEQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNEQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRNEQ stock methods without spending real money on the virtual paper trading platform.